You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Researchers tested blood samples from urgent and routine care patients seen between early February and early July 2020 for SARS-CoV-2 antibodies.
The synbio company offers scale and lower costs in "massive" end markets, SVB Leerink analysts said, and could soon command an even more attractive valuation.
The newly public company has attracted attention from both investors and competitors for its technology platform used in antibody discovery workflows.
The deal enables Genosity to add Olink's proteomics technology with next-generation sequencing readout to its repertoire of services.
A portion of patients with life-threatening COVID-19 pneumonia had inborn errors of TLR3- and IRF7-dependent type I IFN immunity.
Wall Street analysts are bullish on the firm's cell selection platform technology, which could find a total addressable market of more than $20 billion.
The Bay Area DNA synthesis company said it was "not significantly affected" by the COVID-19 pandemic and beat Wall Street revenue estimates.
The cancer therapy developer has asked a US federal court to declare that its Illuminox platform does not infringe Illumina's trademarks.
According to the registry's first dataset, more than 65 million tests have been manufactured and shipped across the US.
Twist will give Takeda access to its phage display libraries to help Takeda discover and validate antibodies needed for the development of new biologics.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.